Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Overall adverse events · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

ALK inhibitor showed no clear difference in overall adverse events compared with any cytotoxic chemotherapy (low certainty).

1 finding from 1 review

Overall adverse events · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

Next‐generation ALK inhibitor showed no clear difference in overall adverse events compared with crizotinib (moderate certainty).

1 finding from 1 review